
David Crook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6982801/publications.pdf Version: 2024-02-01



DAVID CROOK

#	Article	IF	CITATIONS
1	Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis, 1993, 98, 83-90.	0.4	482
2	The Effects of Different Formulations of Oral Contraceptive Agents on Lipid and Carbohydrate Metabolism. New England Journal of Medicine, 1990, 323, 1375-1381.	13.9	391
3	Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. American Journal of Obstetrics and Gynecology, 1992, 166, 950-955.	0.7	200
4	Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. American Journal of Medicine, 1995, 99, 459-464.	0.6	146
5	Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. Maturitas, 2015, 81, 62-68.	1.0	130
6	Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis, 1992, 92, 41-47.	0.4	112
7	Hormone replacement therapy with dydrogesterone and 17beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. BJOG: an International Journal of Obstetrics and Gynaecology, 1997, 104, 298-304.	1.1	95
8	Hormone Replacement Therapy and the Cardiovascular System. Drugs, 1994, 47, 35-41.	4.9	82
9	Safety Evaluation of Modern Oral Contraceptives. Contraception, 1998, 57, 189-201.	0.8	60
10	7 Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids. Bailliere's Clinical Endocrinology and Metabolism, 1990, 4, 851-875.	1.0	51
11	Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception, 1995, 52, 143-149.	0.8	47
12	Occlusive Vascular Diseases in Oral Contraceptive Users. Drugs, 2000, 60, 721-869.	4.9	46
13	A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. American Journal of Obstetrics and Gynecology, 1993, 169, 1183-1189.	0.7	43
14	Insuline resistance, lipoproteins, body fat and hemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. Journal of the American College of Cardiology, 1994, 23, 377-383.	1.2	43
15	Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. American Journal of Obstetrics and Gynecology, 1994, 170, 1528-1536.	0.7	42
16	Effects of gender, age and menopausal status on serum apolipoprotein concentrations. Clinical Endocrinology, 2016, 85, 733-740.	1.2	40
17	Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Current Opinion in Lipidology, 1994, 5, 48-58.	1.2	37
18	Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. American Journal of Obstetrics and Gynecology, 1994, 170, 1528-1536.	0.7	30

DAVID CROOK

#	Article	IF	CITATIONS
19	Elevated serum lipoprotein(a) levels in young women with endometriosis. Metabolism: Clinical and Experimental, 1997, 46, 735-739.	1.5	29
20	A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 948-953.	1,1	25
21	Low-dose oral contraceptives and carbohydrate metabolism. American Journal of Obstetrics and Gynecology, 1990, 163, 348-353.	0.7	23
22	Clinical and metabolic considerations of long-term oral contraceptive use. American Journal of Obstetrics and Gynecology, 1992, 166, 1955-1963.	0.7	23
23	A Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates. Pediatric Cardiology, 2016, 37, 14-23.	0.6	23
24	4 Oestrogens and atherosclerotic vascular disease—local vascular factors. Bailliere's Clinical Endocrinology and Metabolism, 1993, 7, 47-59.	1.0	22
25	Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. Contraception, 1997, 55, 219-224.	0.8	19
26	Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype. Metabolism: Clinical and Experimental, 1995, 44, 1481-1488.	1.5	16
27	Improving peer review. Primary Health Care Research and Development, 2006, 7, 1-2.	0.5	9
28	Progestogens, lipid metabolism and hormone replacement therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 1991, 98, 749-750.	1.1	8
29	Do different brands of oral contraceptives differ in their effects on cardiovascular disease?. BJOG: an International Journal of Obstetrics and Gynaecology, 1997, 104, 516-520.	1.1	8
30	Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in Type IIa hypercholesterolemia. Cardiovascular Drugs and Therapy, 1992, 6, 633-639.	1.3	7
31	Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, highâ€density lipoprotein subfractions and apolipoproteins in postmenopausal women in a twoâ€year, randomized, doubleâ€blind, placeboâ€controlled trial. Clinical Endocrinology, 2020, 92, 303-311.	1.2	7
32	Pulsatility Index in Internal Carotid Artery in Relation to Transdermal Oestradiol and Time Since Menopause. Obstetrical and Gynecological Survey, 1992, 47, 349.	0.2	6
33	Simvastatin and lipoprotein(a). Lancet, The, 1992, 339, 313-314.	6.3	5
34	Procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II. Thrombosis and Haemostasis, 2008, 100, 391-396.	1.8	4
35	Dietary polyunsaturated fatty acids and aortic plaques. Lancet, The, 1995, 345, 256-257.	6.3	3
36	Prescribing oral contraceptives. Nature, 1996, 379, 764-764.	13.7	1

#	Article	IF	CITATIONS
37	Estrogens used in current menopausal therapies. , 2015, , 118-123.		1
38	The oestrogen component of currently used steroidal contraceptives. , 0, , 35-41.		0
39	Effects of gender and menopausal status on serum apolipoprotein concentrations. Endocrine Abstracts, 0, , .	0.0	0